TECH vs BBIO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TECH · Bio-Techne$72.78 ▲ 0.17%
BBIO · BridgeBio Pharma$74.29 ▲ 0.03%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TECH +27.4%
- BBIO +18.3%
Head to head
| Metric | TECH | BBIO |
|---|---|---|
| Price | $72.78 | $74.29 |
| Change today | ▲ 0.17% | ▲ 0.03% |
| Market cap | $11.43B | $14.47B |
| Return, 3 months | +1.0% | -12.3% |
| Return, year to date | +24.3% | -2.9% |
| Return, 1 year | +27.5% | +20.2% |
| P/E (TTM) | 62.7 | – |
| P/B | 5.4 | -5.6 |
| P/E percentile vs own 5y | 50th | 0th |
| Dividend yield | 0.44% | – |
| Revenue growth (YoY, latest qtr) | +1.3% | +120.4% |
| Net profit growth (YoY) | +409.0% | +15.2% |
| Gross margin | 65.8% | 94.4% |
| Operating margin | 22.4% | -67.0% |
| Net margin | 15.0% | -97.0% |
| Return on equity | 9.0% | – |
| Analyst target vs. price | +0.3% | +47.7% |
| Analyst buy share | 0% | 94% |
| RSI (14) | 61 | 60 |
| 30-day volatility | 1.9% | 35.2% |
| Max drawdown, 1 year | -39.3% | -29.8% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Sell | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BBIO is the largest of the group by market value.
- TECH has returned the most over the past year.
- BBIO is growing revenue fastest.
- TECH keeps the most profit per dollar of sales.
- TECH has been the calmest stock over the last 30 days.